The issuer advises that the following release replaces the Block Admission Application announcement released at 7:01 a.m. on 24 February 2022. The number of shares applied for under the block admission has been corrected to 2,063,200, no other changes have been made. The corrected announcement is set out in full below:

24 February 2022

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Block Admission Application

Aptamer Group plc (AIM: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, announces that a block admission application has been made to the London Stock Exchange for up to 2,063,200 ordinary shares of 0.1 pence each to be admitted to trading on AIM ("Admission").

The application is being made in respect of Shares that will be issued from time to time by the Company in relation to the exercise of share options granted under the terms of The Aptamer Group EMI Share Option Scheme. When issued, the Shares will rank pari passu in all respects with the existing issued ordinary shares of the Company.

Admission is expected to become effective at 08:00 a.m. on 25 February 2022.

Total Voting Rights

The Company intends to notify on a monthly basis when there are changes to the issued share capital of the Company, and these monthly figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company, under the FCA's Disclosure Guidance and Transparency Rules.

- ENDS -

For further information, please contact:

[email protected]

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer^® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145bn. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.